One report also showed that PD-L1 was upregulated in HCCs upon JQ1 treatment both in vivo and in vitro, while the combination therapy of JQ1 with anti-PDL1 antibodies in a transgenic HCC model resulted in significant attenuation of tumor growth that correlated with reduction of Ki-67-positive tumor cells in a transgenic HCC model (Liu et al., 2020). This evidence concerns the gene CD274 and hepatocellular carcinoma.